Intangible Assets

6 Months Ended

Mar. 31, 2014

Goodwill And Intangible Assets Disclosure [Abstract]

5.	Intangible Assets

A summary of our acquired intangible assets subject to amortization, as of March 31, 2014 and September 30, 2013 is as follows:


	March 31, 2014				September 30, 2013
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	11,723	$	10,375	$	11,676	$	10,097
Trademarks, licenses and patents		6,474		2,481		4,748		2,130
Customer lists and supply agreements		12,481		8,981		12,353		8,493

	$	30,678	$	21,837	$	28,777	$	20,720

During the first quarter of fiscal 2014, we acquired the remaining licensing rights related to our illumigene molecular technology for $1,638. These rights are being amortized over a weighted average period of approximately 8.5 years.

The actual aggregate amortization expense for these intangible assets was $516 and $585 for the three months ended March 31, 2014 and 2013, respectively, and $1,042 and $1,165 for the six months ended March 31, 2014 and 2013, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2019 is as follows: remainder of fiscal 2014 – $967, fiscal 2015 – $1,777, fiscal 2016 – $1,432, fiscal 2017 – $1,163, fiscal 2018 – $1,140 and fiscal 2019 – $1,099.